Literature DB >> 30975585

Comparison of perinatal outcomes following blastocyst and cleavage-stage embryo transfer: analysis of 10 years' data from a single centre.

Wenhao Shi1, Wei Zhang2, Na Li3, Xia Xue3, Chen Liu4, Pengfei Qu3, Juanzi Shi3, Chen Huang5.   

Abstract

RESEARCH QUESTION: Are there greater risks of adverse perinatal outcomes, in particular of congenital malformations, after blastocyst transfer compared with cleavage-stage embryo transfer in IVF?
DESIGN: This was a retrospective cohort analysis from a centre for assisted reproduction at a public hospital in China over the period 2006-2015. The analysis covered all women who conceived (15,254) and newborns (16,213) from IVF/intracytoplasmic sperm injection (ICSI) cycles with cleavage-stage embryo transfer or blastocyst transfer. The principal outcome measures were congenital malformations, preterm birth (PTB), low birthweight (LBW), small for gestational age (SGA) and large for gestational age (LGA).
RESULTS: Logistic regression analysis showed that the sex ratio was imbalanced towards male neonates after blastocyst transfer (P=0.001; adjusted OR 1.17, 95%CI 1.07-1.30) but there were no differences in rates of miscarriage, ectopic pregnancy, stillbirth, very preterm birth (<32 weeks), PTB (<37 weeks), LBW, SGA or LGA between blastocyst transfer and cleavage-stage embryo transfer. A total of 176 congenital malformations (123 cleavage-stage embryos versus 53 blastocysts) were identified both in newborns and aborted fetuses, but the difference between groups was not statistically significant.
CONCLUSIONS: There was no difference in the risks of adverse perinatal outcomes, and in particular of congenital malformation, after blastocyst transfer compared with cleavage-stage transfer, although there was a sex ratio imbalance towards male neonates after blastocyst transfer.
Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Birth defects; Blastocyst transfer; Cleavage-stage embryo transfer; Congenital malformations; In-vitro fertilization

Mesh:

Year:  2019        PMID: 30975585     DOI: 10.1016/j.rbmo.2018.12.031

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

1.  Blastocyst versus cleavage transfers: who benefits?

Authors:  Enver Kerem Dirican; Safak Olgan; Mehmet Sakinci; Mete Caglar
Journal:  Arch Gynecol Obstet       Date:  2021-09-06       Impact factor: 2.344

2.  Early Spontaneous Abortion in Fresh- and Frozen-Embryo Transfers: An Analysis of Over 35,000 Transfer Cycles.

Authors:  Jun Shuai; Qiao-Li Chen; Wen-Hong Chen; Wei-Wei Liu; Guo-Ning Huang; Hong Ye
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-27       Impact factor: 6.055

3.  The duration of embryo culture after mouse IVF differentially affects cardiovascular and metabolic health in male offspring.

Authors:  Anan Aljahdali; R K Raja Ili Airina; Miguel A Velazquez; Bhavwanti Sheth; Katrina Wallen; Clive Osmond; Adam J Watkins; Judith J Eckert; Neil R Smyth; Tom P Fleming
Journal:  Hum Reprod       Date:  2020-11-01       Impact factor: 6.918

4.  Effect of the Interaction Between Pre-pregnancy Body Mass Index and Fresh/Frozen Embryo Transfer on Perinatal Outcomes of Assisted Reproductive Technology-Conceived Singletons: A Retrospective Cohort Study.

Authors:  Pengfei Qu; Yang Mi; Doudou Zhao; Min Wang; Shaonong Dang; Wenhao Shi; Juanzi Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-25       Impact factor: 5.555

5.  Preterm Birth in Assisted Reproductive Technology: An Analysis of More Than 20,000 Singleton Newborns.

Authors:  Zhiqin Bu; Jiaxin Zhang; Linli Hu; Yingpu Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-07       Impact factor: 5.555

6.  Association Between Pre-Pregnancy Body Mass Index and Miscarriage in an Assisted Reproductive Technology Population: A 10-Year Cohort Study.

Authors:  Pengfei Qu; Mingxin Yan; Doudou Zhao; Dongyang Wang; Shaonong Dang; Wenhao Shi; Juanzi Shi; Chunli Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.